5. Culturally Competent Care for Substance Users Diagnosed with HIV Disease
References
National Institute on Drug Abuse; International AIDS Society. Meeting report: prevention and treatment of HIV/AIDS among drug-using populations: a global perspective. Available at: http://nidahivaids.seiservices.com/. Accessed February 11, 2012.
McNeil JI. A model for cultural competency in the HIV management of African American patients. J Natl Med Assoc. 2003;95:3S-7S.
Celentano DD, Lucas G. Optimizing treatment outcomes in HIV-infected patients with substance abuse issues. Clin Infect Dis. 2007;45:S318-323.
Nijhawan A, Kim S, Rich JD. Management of HIV infection in patients with substance use problems. Curr Infect Dis Rep. 2008;10:432-438.
Shannon K, Kerr T, Lai C, et al. Nonadherence to antiretroviral therapy among a community with endemic rates of injection drug use. J Int Assoc Physicians AIDS Care. 2005;4:66-72.
Lum PJ, Tulsky JP. The medical management of opioid dependence in HIV primary care settings. Curr HIV/AIDS Rep. 2006;3:195-204.
Khalsa J, Vocci F, Altice F, et al. Buprenorphine and HIV primary care: new opportunities for integrated treatment. Clin Infect Dis. 2006;43:S169-S172.
Zaller N, Gillani FS, Rich JD. A model of integrated primary care for HIV-positive patients with underlying substance use and mental illness. AIDS Care. 2007;19:1128-1133.
Bouis S, Reif S, Whetten K, et al. An integrated, multidimensional treatment model for individuals living with HIV, mental illness, and substance abuse. Health Soc Work. 2007;32:268-278.
Basu S, Smith-Rohrberg D, Bruce RD, Altice FL. Models for integrating buprenorphine therapy into the primary HIV care setting. Clin Infect Dis. 2006;42:716-721.
Chander G, Lau B, Moore RD. Hazardous alcohol use: a risk factor for non-adherence and lack of suppression in HIV infection. J Acquir Immune Defic Syndr. 2006;43:411-417.
Hicks PL, Mulvey KP, Chander G, et al. The impact of illicit drug use and substance abuse treatment on adherence to HAART. AIDS Care. 2007;19:1134-1140.
Wartenberg AA. HIV disease in the intravenous drug user: role of the primary care physician. J Gen Intern Med. 1991;6:S35-S40.
Vocci FJ, Acri J, Elkashef A. Medication development for addictive disorders: the state of the science. Am J Psychiatry. 2005;162:1432-1440.
Francis H. Substance abuse and HIV infection. Top HIV Med. 2003;11:20-24.
Fiellin DA. Substance use disorders in HIV-infected patients: impact and new treatment strategies. Top HIV Med. 2004;12:77-82.
Celentano DD, Vlahov D, Cohn S, et al. Self-reported antiretroviral therapy in injection drug users. JAMA. 1998;280:544-546.
Strathdee SA, Palepu A, Cornelisse PG, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA. 1998;280:547-549.
Bouhnik AD, Chesney M, Carrieri P, et al. Nonadherence among HIV-infected injecting drug users: the impact of social instability. J Acquir Immune Defic Syndr. 2002;31:S149-S153.
Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: www.aidsinfo.nih.gov/guidelines. Accessed February 17, 2012.
Carrieri MP, Villes V, Raffi F, et al. Self-reported side-effects of anti-retroviral treatment among IDUs: a 7-year longitudinal study (APROCO-COPILOTE COHORT ANRS CO-8). Int J Drug Policy. 2007;18:288-295.
Selwyn PA, Feingold AR, Hartel D, et al. Increased risk of bacterial pneumonia in HIV-infected intravenous drug users without AIDS. AIDS. 1988;2:267-272.
Gordon RJ, Lowy FD. Bacterial infections in drug users. N Engl J Med. 2005;353:1945-1954.
Brett MM, Hood J, Brazier JS, et al. Soft tissue infections caused by spore-forming bacteria in injecting drug users in the United Kingdom. Epidemiol Infect. 2005;133:575-582. [PubMed: 16050501]
Wilson LE, Thomas DL, Astemborski J, et al. Prospective study of infective endocarditis among injection drug users. J Infect Dis. 2002;185:1761-1766.
Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol. 2006;44:S6-S9.
Braitstein P, Justice A, Bangsberg DR, et al. Hepatitis C coinfection is independently associated with decreased adherence to antiretroviral therapy in a population-based HIV cohort. AIDS. 2006;20:323-331.
Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part II: immunization of adults. MMWR Recomm Rep. 2006;55:1-33.
Tegger MK, Crane HM, Tapia KA, et al. The effect of mental illness, substance use, and treatment for depression on the initiation of highly active antiretroviral therapy among HIV-infected individuals. AIDS Patient Care STDS. 2008;22:233-243.
Mijch A, Burgess P, Judd F, et al. Increased health care utilization and increased antiretroviral use in HIV-infected individuals with mental health disorders. HIV Med. 2006;7:205-212.
Weaver MR, Conover CJ, Proescholdbell RJ, et al. Utilization of mental health and substance abuse care for people living with HIV/AIDS, chronic mental illness, and substance abuse disorders. J Acquir Immune Defic Syndr. 2008;47:449-458.
Bruce RD, Altice FL. Clinical care of the HIV-infected drug user. Infect Dis Clin North Am. 2007;21:149-179.